癌症支持治療藥物市場規模、佔有率和成長分析（按治療類別、應用、通路和地區分類）－2026-2033年產業預測

預計到 2024 年，癌症支持治療藥物市場規模將達到 224 億美元，到 2025 年將達到 230.7 億美元，到 2033 年將達到 292.3 億美元，預測期（2026-2033 年）的複合年成長率為 3%。

全球癌症輔助治療藥物市場對於緩解癌症治療相關的副作用、提高患者的生活品質至關重要。由於化療和放射線治療等癌症治療常常會引起嚴重的副作用，輔助治療藥物在症狀管理中發揮關鍵作用。隨著癌症發病率的上升、人口老化以及治療方法的進步，該市場正經歷顯著的擴張。這一類別涵蓋了多種藥物，包括止吐藥、鎮痛藥和血液病藥物。持續的研發對於開發更具針對性的治療方法至關重要，而製藥公司之間的合作旨在提供綜合治療方案。以患者為中心的醫療模式日益受到重視，這推動了對以患者舒適度為優先的高效輔助治療的需求。

癌症支持治療藥物市場促進因素

全球癌症發生率的不斷上升是癌症支持治療藥物需求成長的主要促進因素。隨著越來越多的患者接受包括化療、放射線治療和標靶治療在內的各種癌症治療，應對這些治療相關副作用的需求也日益成長。支持治療藥物在緩解癌症治療過程中出現的噁心、疼痛、貧血和疲勞等症狀方面發揮著至關重要的作用，從而提高患者的生活品質。人們越來越重視患者的舒適度和健康促進，這凸顯了在整個癌症治療過程中提供支持性治療方案的重要性。

癌症支持治療市場的限制

癌症輔助治療藥物帶來的經濟負擔給市場帶來了巨大挑戰。這些藥物的高昂價格推高了癌症治療的整體成本，並可能導致患者無法獲得所需的治療。在醫療保險和政府資助的醫療保健項目涵蓋範圍有限的地區，這個問題尤其突出。因此，許多患者不願意服用這些必需藥物，這會影響他們有效應對癌症治療副作用的能力，並損害他們的整體健康。因此，藥物的可近性和可負擔性仍然是該領域的主要關注點。

癌症支持治療藥物市場趨勢

癌症支持治療藥物市場正呈現出向個人化支持治療方案發展的顯著趨勢，這主要得益於人們對個別患者需求的日益深入了解。隨著治療方法的個人化程度不斷提高，針對特定副作用（例如噁心、嘔吐、疼痛、疲勞和貧血）的藥物需求也日益成長，這些副作用的緩解取決於患者的癌症類型和治療通訊協定。這一趨勢推動了腫瘤治療領域以患者為中心的理念，凸顯了開發標靶支持治療的重要性，這些治療能夠提高患者的生活品質，增強治療依從性，並最終改善患者的健康結果。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 專利分析

全球癌症支持治療藥物市場規模（按治療分類及複合年成長率分類）（2026-2033 年）

• 顆粒細胞增生因子（G-CSF）
• 紅血球生成刺激因子（ESA）
• 止吐藥
• 雙磷酸鹽
• 鴉片類藥物
• 非類固醇消炎劑（NSAIDs）

全球癌症支持治療藥物市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 化療引起的噁心和嘔吐（CINV）
• 化療引起的貧血
• 化療引起的嗜中性白血球低下症
• 骨轉移
• 癌症疼痛
• 其他

全球癌症支持治療藥物市場規模（按通路和複合年成長率分類）（2026-2033 年）

• 醫院藥房
• 零售藥房
• 網路藥房

全球癌症支持治療藥物市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Amgen Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson Services, Inc.（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Sanofi（France）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Helsinn Healthcare（Switzerland）
• Heron Therapeutics, Inc.（USA）
• Acacia Pharma Group Plc（UK）
• Sun Pharmaceutical Industries Ltd.（India）
• Celldex Therapeutics（USA）
• Ipsen Pharma（France）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Mylan NV（USA）
• Dr. Reddy's Laboratories Ltd.（India）
• Eli Lilly and Company（USA）

結論與建議

Cancer Supportive Care Drugs Market size was valued at USD 22.4 Billion in 2024 and is poised to grow from USD 23.07 Billion in 2025 to USD 29.23 Billion by 2033, growing at a CAGR of 3% during the forecast period (2026-2033).

The global market for cancer supportive care drugs is essential for alleviating the adverse effects associated with cancer treatments and enhancing the quality of life for patients. As cancer therapies such as chemotherapy and radiation often induce significant side effects, supportive care drugs play a vital role in symptom management. The market has experienced notable expansion driven by the rising incidence of cancer, an aging demographic, and advancements in treatment modalities. This sector includes a diverse array of pharmaceuticals, such as antiemetics, analgesics, and hematopoietic agents. Ongoing research and development are pivotal for creating more targeted therapies, while collaborative efforts among pharmaceutical companies aim to deliver integrated treatment options. The growing focus on patient-centered care underscores the increasing need for effective supportive therapies that prioritize patient comfort.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Supportive Care Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Supportive Care Drugs Market Segments Analysis

Global Cancer Supportive Care Drugs Market is segmented by Therapeutic Class, Application, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into Granulocyte Colony-Stimulating Factors (G-CSFs), Erythropoiesis-Stimulating Agents (ESAs), Antiemetics, Bisphosphonates, Opioids and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Based on Application, the market is segmented into Chemotherapy-Induced Nausea and Vomiting (CINV), Chemotherapy-Induced Anemia, Chemotherapy-Induced Neutropenia, Bone Metastasis, Cancer Pain and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Supportive Care Drugs Market

The growing incidence of cancer worldwide significantly drives the demand for cancer supportive care drugs. As more individuals undergo various cancer treatments, including chemotherapy, radiation, and targeted therapies, there is an escalating need to manage the adverse effects associated with these interventions. Supportive care medications play a crucial role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue experienced during their cancer treatment journey. This rising focus on improving patient comfort and well-being underscores the importance of supportive care options in the overall cancer care continuum.

Restraints in the Cancer Supportive Care Drugs Market

The financial burden associated with cancer supportive care drugs poses a significant challenge in the market. The high prices of these medications can escalate the overall expenses of cancer treatment, making it difficult for patients to afford the necessary care. This issue is particularly pronounced in regions with limited access to healthcare insurance or government-assisted healthcare programs. As a result, many patients may be deterred from using these essential drugs, which can hinder their ability to effectively manage the side effects of their cancer treatments and compromise their overall well-being. Accessibility and affordability thus remain major concerns in this segment.

Market Trends of the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs market is witnessing a notable trend toward personalized supportive care solutions, reflecting a deeper understanding of patient-specific needs in the realm of cancer treatment. As therapies become increasingly individualized, there is a growing demand for medications specifically tailored to manage distinct side effects such as nausea, vomiting, pain, fatigue, and anemia, contingent on the patient's cancer type and treatment protocol. This trend emphasizes the importance of developing targeted supportive care therapies that enhance patients' quality of life, improve treatment adherence, and ultimately yield better health outcomes, fostering a more patient-centric approach in oncology care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Supportive Care Drugs Market Size by Therapeutic Class & CAGR (2026-2033)

• Market Overview
• Granulocyte Colony-Stimulating Factors (G-CSFs)
• Erythropoiesis-Stimulating Agents (ESAs)
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Global Cancer Supportive Care Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Chemotherapy-Induced Anemia
• Chemotherapy-Induced Neutropenia
• Bone Metastasis
• Cancer Pain
• Others

Global Cancer Supportive Care Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cancer Supportive Care Drugs Market Size & CAGR (2026-2033)

• North America (Therapeutic Class, Application, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Healthcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acacia Pharma Group Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations